G-FINDER report shows European Commission increased funding for poverty-related and neglected disease research for second consecutive year
The European Commission increased its funding for poverty-related and neglected diseases (PRND) research and development (R&D) for the second consecutive year, becoming the third-largest public funder globally for this research behind only the US and UK.
Policy Cures Research released its latest annual G-FINDER Report for 2019 which reviewed funding in 2018 for diseases that affect low-income countries. The report found that funding was up overall, mirroring trends from the world’s top three donors. Investment from pharmaceutical companies has also reached its highest level ever. However, while funding for HIV, tuberculosis, and malaria grew, R&D spending for neglected tropical diseases has decreased over the decade, down by 10% compared to 2009.
The Commission’s funding for R&D is channelled through Horizon 2020, its research framework program. Most of the funding was spent through Horizon’s 2020’s European & Developing Countries Clinical Trials Partnership (EDCTP), which provided €114 million (US$127 million) in funding for PRND in 2018, or 5.2% of all global public sector funding. Most of EDCTP’s spending was for research on tuberculosis, kinetoplastid diseases, malaria, helminth infections, and HIV/AIDS, and most focused on clinical development.
The Commission has proposed an EU-Africa Global Health Partnership as a successor for EDCTP under the next EU research framework program, Horizon Europe.